Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.37 Insider Own1.17% Shs Outstand73.40M Perf Week-7.43%
Market Cap100.56M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float72.54M Perf Month-15.95%
Income-24.00M PEG- EPS next Q-0.11 Inst Own8.56% Short Float / Ratio2.05% / 3.67 Perf Quarter-39.38%
Sales0.00M P/S- EPS this Y-8.85% Inst Trans32.54% Short Interest1.49M Perf Half Y-13.84%
Book/sh0.29 P/B4.69 EPS next Y-8.92% ROA-76.87% Target Price5.12 Perf Year-29.02%
Cash/sh0.40 P/C3.40 EPS next 5Y- ROE-113.93% 52W Range1.09 - 3.39 Perf YTD-15.95%
Dividend- P/FCF- EPS past 5Y17.85% ROI-110.59% 52W High-59.64% Beta2.00
Dividend %- Quick Ratio4.53 Sales past 5Y0.00% Gross Margin- 52W Low25.69% ATR0.10
Employees29 Current Ratio4.53 Sales Q/Q- Oper. Margin0.00% RSI (14)37.91 Volatility3.59% 7.17%
OptionableNo Debt/Eq0.02 EPS Q/Q-83.39% Profit Margin- Rel Volume0.67 Prev Close1.40
ShortableYes LT Debt/Eq0.01 EarningsNov 03 BMO Payout- Avg Volume405.38K Price1.37
Recom1.00 SMA20-7.96% SMA50-19.39% SMA200-26.63% Volume271,281 Change-2.14%
Date Action Analyst Rating Change Price Target Change
Oct-06-22Initiated Maxim Group Buy $3
Feb-17-21Initiated H.C. Wainwright Buy $15
Nov-29-23 10:45AM
Nov-09-23 08:45AM
Nov-05-23 02:29PM
12:03PM Loading…
Nov-03-23 12:03PM
Oct-23-23 09:50AM
Oct-20-23 10:31AM
Oct-16-23 07:00AM
Oct-13-23 09:00AM
09:00AM Loading…
Oct-11-23 09:00AM
Sep-26-23 08:00AM
Sep-19-23 07:00AM
Sep-07-23 09:22AM
Sep-06-23 07:00AM
Aug-21-23 07:00AM
Aug-17-23 09:35AM
Aug-14-23 07:00AM
Aug-08-23 08:50AM
Aug-04-23 07:05AM
Jul-31-23 06:55AM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
May-26-23 11:30AM
05:41PM Loading…
May-25-23 05:41PM
May-24-23 10:26AM
May-10-23 07:00AM
May-07-23 01:18PM
May-05-23 07:00AM
Apr-26-23 10:44AM
Apr-12-23 07:23AM
Mar-28-23 07:00AM
Mar-27-23 11:57AM
Mar-06-23 09:48AM
Mar-03-23 07:00AM
Feb-21-23 07:00AM
Dec-16-22 09:40AM
Dec-08-22 08:45AM
Dec-05-22 12:00PM
Dec-02-22 10:59AM
Dec-01-22 07:32AM
Nov-29-22 09:40AM
Nov-21-22 09:01AM
Nov-18-22 09:55AM
Nov-10-22 09:01AM
Nov-07-22 08:03AM
Oct-27-22 07:00AM
Oct-18-22 10:46AM
Sep-07-22 07:00AM
Aug-11-22 07:00AM
Jul-27-22 07:00AM
Jul-11-22 06:19AM
Jun-28-22 07:00AM
Jun-17-22 07:00AM
Jun-01-22 12:21PM
May-11-22 10:19AM
May-10-22 07:00AM
May-05-22 04:01PM
May-04-22 07:00AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-21-22 07:00AM
Apr-14-22 07:00AM
Apr-12-22 07:00AM
Apr-08-22 01:05PM
Apr-06-22 07:00AM
Mar-31-22 07:00AM
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.